Patents Examined by Chun W Dahle
  • Patent number: 10525129
    Abstract: The invention provides a method of treating a patient having target cells that express FcyRIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding FcyRIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and FcyRIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of FcyRIIb.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: January 7, 2020
    Assignee: University of Southampton
    Inventors: Mark Cragg, Martin Glennie, Ali Roghanian, Stephen Beers, Peter Johnson, Sean Lim, Bjorn Frendeus, Ingrid Teige
  • Patent number: 10526408
    Abstract: In some aspects, mutant or variant Fc domains are provided that can exhibit increased affinity or selectivity for Fc?RIIB. The variant Fc domain may be a mutant IgG1 Fc domain. In some embodiments, a mutant or variant Fc domain may be present in a therapeutic antibody such as, e.g., an agonistic antibody. Additional methods for using and identifying mutant Fc domains are also provided.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: January 7, 2020
    Assignee: Research Development Foundation
    Inventors: George Georgiou, Chang-Han Lee
  • Patent number: 10494432
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: December 3, 2019
    Assignee: Genentech, Inc.
    Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
  • Patent number: 10472414
    Abstract: The present invention relates to antibodies specific for pyroglutamated A?, as well as their use in the treatment of Alzheimer's disease and as use in diagnostic methods or as diagnostic imaging ligands. Further, is provided pyroglutamated N-terminal fragments of murine or human A? to generate antibodies and for use in therapeutic purposes.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: November 12, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Søren Christensen, Lone Helboe
  • Patent number: 10457737
    Abstract: Methods and compositions involving polypeptides having an aglycosylated antibody Fc domain are provided. In certain embodiments, polypeptides have an aglycosylated Fc domain that contains one or more substitutions compared to a native Fc domain. Additionally, some embodiments involve an Fc domain that is binds some Fc receptors but not others. For example, polypeptides are provided with an aglycosylated Fc domain that selectively binds C1q, and optionally activating Fc receptors, but that is significantly reduced for binding to the inhibitory Fc?RIIb receptor. Furthermore, methods and compositions are provided for promoting complement dependent cytotoxicity (CDC) using a polypeptide having a modified aglycosylated Fc domain and a second non-Fc binding domain, which can be an antigen binding region of an antibody or a non-antigen binding region. Some embodiments concern antibodies with such polypeptides, which may have the same or a different non-Fc binding domain.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: October 29, 2019
    Assignee: Research Development Foundation
    Inventors: George Georgiou, Chang-Han Lee
  • Patent number: 10457742
    Abstract: The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: October 29, 2019
    Assignee: ZYMEWORKS INC.
    Inventors: Thomas Spreter Von Kreudenstein, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Paula Irene Lario, David Kai Yuen Poon
  • Patent number: 10435471
    Abstract: The invention provides anti-FcRH5 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: October 8, 2019
    Assignee: Genentech, Inc.
    Inventors: Allen J. Ebens, Meredith C. Hazen, Jo-Anne Hongo, Jennifer W. Johnston, Teemu T. Junttila, Ji Li, Andrew G. Polson
  • Patent number: 10407505
    Abstract: The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: September 10, 2019
    Assignee: Seattle Genetics, Inc.
    Inventors: Paul Carter, Django Sussman
  • Patent number: 10407499
    Abstract: The present invention provides an anti-FcyRIIB antibodies which, in comparison to prior art antibodies, markedly increase ITIM phosphorylation of FcyRIIB and can thus be used for the treatment or prophylaxis of autoimmune diseases.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: September 10, 2019
    Assignee: SUPPREMOL GMBH
    Inventors: Peter Sondermann, Thomas Pohl, Dominik Ter Meer, Anna Carle, Daniela Ehehalt, Nicole Rieth
  • Patent number: 10344092
    Abstract: The present invention is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc Domain (“bi-specific monovalent Fc diabodies”) and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of CD32B and one binding site specific for an epitope of CD79b (i.e., a “CD32B×CD79b bi-specific monovalent Fc diabody”). The bi-specific monovalent Fc diabodies of the present invention are capable of simultaneous binding to CD32B and CD79b. The invention is directed to such compositions, to pharmaceutical compositions that contain such bi-specific monovalent Fc diabodies and to methods for their use in the treatment of inflammatory diseases or conditions, and in particular, systemic lupus erythematosus (SLE) and graft vs. host disease.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: July 9, 2019
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang, Kalpana Shah, Ezio Bonvini, Paul A. Moore, Wei Chen
  • Patent number: 10336818
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: July 2, 2019
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Patent number: 10336825
    Abstract: The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: July 2, 2019
    Assignee: HANALL BIOPHARMA CO., LTD.
    Inventors: Sung Wuk Kim, Seung Kook Park, Jae Kap Jeong, Hyea Kyung Ahn, Min Sun Kim, Eun Sun Kim, Hae-Young Yong, Dongok Shin, Yeon Jung Song, Tae Hyoung Yoo
  • Patent number: 10323094
    Abstract: The present invention relates to anti-FcRH5 antibodies, including anti-FcRH5 antibodies comprising an FcRH5 binding domain and a CD3 binding domain (e.g., FcRH5 T cell-dependent bispecific (TDB) antibodies), and methods of using the same.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: June 18, 2019
    Assignee: Genentech, Inc.
    Inventors: Isidro Hotzel, Teemu T. Junttila, Ji Li, Justin Scheer, Danielle DiCara, Diego Ellerman, Christoph Spiess, Paul J. Carter
  • Patent number: 10316073
    Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: June 11, 2019
    Assignees: argenx BVBA, The Board of Regents of the University of Texas System
    Inventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
  • Patent number: 10307481
    Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
    Type: Grant
    Filed: July 25, 2006
    Date of Patent: June 4, 2019
    Assignee: Aptevo Research and Development LLC
    Inventors: Laura S. Grosmaire, Martha S. Hayden-Ledbetter, Jeffrey A. Ledbetter, Peter A. Thompson, Sandy A. Simon, William Brady
  • Patent number: 10280207
    Abstract: The present invention relates to a human antibody specific for FcRn that is a receptor with a high affinity for IgG, a production method thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune disease using the same. The FcRn-specific antibody according to the present invention can bind to FcRn non-competitively with IgG or the like to reduce serum auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: May 7, 2019
    Assignee: HANALL BIOPHARMA CO., LTD.
    Inventors: Sung Wuk Kim, Seung Kook Park, Jae Kap Jeong, Min Sun Kim, Eun Sun Kim, Jeong Haing Heo, Yeon Jung Song, Hae-Young Yong, Dongok Shin
  • Patent number: 10273302
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: April 30, 2019
    Assignee: UCB Biopharma SPRL
    Inventors: Paul Alan Atherfold, Thomas Allen Ceska, Helene Margaret Finney, Lara Kevorkian, Kaushik Sarkar, Bryan John Smith, Kerry Louise Tyson
  • Patent number: 10259886
    Abstract: The present application relates to antigen-binding proteins that are capable of binding to mammalian IgG. The frame-work regions of the antigen-binding proteins of the application preferably correspond to those of antibodies naturally that are devoid of light chains as may e.g. be found in camelids. The application further relates to nucleic acids that encode such antigen-binding proteins, to immunoadsorbent materials that comprise such proteins, to the uses of such immunoadsorbent materials for the purification of mammalian IgG antibodies and for therapeutic apheresis.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: April 16, 2019
    Assignee: BAC IP B.V.
    Inventors: Wilhelmus Josephus Johanna Hermans, Sandra Bezemer, Yvonne Mathalie Mijnsbergen
  • Patent number: 10259871
    Abstract: The present disclosure provides antibodies specific for an epitope present on CD22. The antibodies are useful in various treatment, diagnostic, and monitoring applications, which are also provided.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: April 16, 2019
    Assignee: Redwood Bioscience, Inc.
    Inventors: David Rabuka, Robert George Edward Holgate, Francis Joseph Carr
  • Patent number: 10251942
    Abstract: An immunity-inducing agent comprising as an effective ingredient(s) a polypeptide(s) selected from the polypeptides: (a) a polypeptide consisting essentially of not less than 7 consecutive amino acids in any one of the amino acid sequences shown in SEQ ID NOs:2, 4, 6, 8, 10, 12 and 44 in SEQUENCE LISTING; (b) a polypeptide having a sequence identity of not less than 90% with the polypeptide (a) and consisting essentially of not less than 7 amino acids; and (c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof; which polypeptide(s) has/have an immunity-inducing activity/activities, or as an effective ingredient(s) a recombinant vector(s) which comprise(s) a polynucleotide(s) encoding the polypeptide(s) and is/are capable of expressing the polypeptide(s) in vivo, is useful as a therapeutic and/or prophylactic agent for cancer, and/or the like.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: April 9, 2019
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Akira Kurihara, Fumiyoshi Okano